Myriad partners with OptraHealth for AI-based cancer information tool

Myriad Genetics (NASDAQ:MYGN) partners with OptraHEALTH to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients.

Gene interfaces with Myriad’s market-leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

Shares are up 3.4% premarket to $11.97

Source: Press Release

https://seekingalpha.com/news/3588664-myriad-partners-optrahealth-for-ai-based-information-tool-for-hereditary-cancer-patients